A study published in Economic Evaluation in October 2022 found that over the lifetime of 40 birth cohorts, China’s immunization program is preventing 93% of pertussis cases and 97% of pertussis deaths, resulting in substantial savings to the healthcare system and society.
This study aimed to evaluate the economic impact of diphtheria, tetanus, whole-cell pertussis vaccine and diphtheria-tetanus-acellular pertussis vaccine vaccination for children on the prevention of pertussis in China’s 40-year immunization program.
Without the implementation of the pertussis immunization program in China, the model estimated 115.76 million pertussis cases and 426,650 deaths in the 40 newborn cohorts.
In the presence of the program, the number of cases and deaths of pertussis would decrease by 92.57% and 97.43%, respectively, and US$46 987.81 million and US$82 013.37 million would be averted from direct cost and societal perspective, respectively.
The benefit-cost ratios for preventing pertussis were 21.67:1 from the direct cost perspective and 20.70:1 from the societal perspective.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.